<SEC-DOCUMENT>0000950170-25-112266.txt : 20250829
<SEC-HEADER>0000950170-25-112266.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250829170202
ACCESSION NUMBER:		0000950170-25-112266
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250829
DATE AS OF CHANGE:		20250829

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-40908
		FILM NUMBER:		251281828

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGENUS INC
		CENTRAL INDEX KEY:			0001098972
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				061562417
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-674-4410

	MAIL ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIGENICS INC /DE/
		DATE OF NAME CHANGE:	19991115
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001098972</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001840229</issuerCik>
<issuerName>MiNK Therapeutics, Inc</issuerName>
<secFileNumber>001-40908</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">149 Fifth Avenue</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">Suite 500</street2>
<city xmlns="http://www.sec.gov/edgar/common">New York</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10010</zipCode>
</issuerAddress>
<issuerContactPhone>212-994-8250</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Agenus Inc.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Owner</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>B. Riley Financial</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">11000 Santa Monica Blvd,</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">Suite 800,</street2>
<city xmlns="http://www.sec.gov/edgar/common">Los Angeles,</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">90025</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>786750</noOfUnitsSold>
<aggregateMarketValue>12572265.00</aggregateMarketValue>
<noOfUnitsOutstanding>3966392</noOfUnitsOutstanding>
<approxSaleDate>08/29/2025</approxSaleDate>
<securitiesExchangeName>INKT</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>07/05/2017</acquiredDate>
<natureOfAcquisitionTransaction>These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc.</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>MiNK Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>1948100</amountOfSecuritiesAcquired>
<paymentDate>07/05/2017</paymentDate>
<natureOfPayment>These shares were acquired in exchange for Agenus Inc.'s initial capital contribution.</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<remarks>EXPLANATION OF RESPONSES:
1. Agenus has no current intention to sell shares at prevailing market prices but seeks to preserve flexibility should market conditions change.  The filing of this form does not represent an immediate sale plan.
2. Fair market value, of shares that may be sold, estimate based on the closing price of the Issuer's common stock on 8/27/2025 at $15.98.
3. In the event any sales of shares are made they must be completed within 90 days of the date of this filing.
4. These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc.
5. These shares were acquired in exchange for Agenus Inc.'s initial capital contribution.</remarks>
<noticeSignature>
<noticeDate>08/29/2025</noticeDate>
<signature>/s/ Garo Armen</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
